Immunocore Holdings (IMCR) Receivables - Net (2019 - 2026)

Immunocore Holdings has reported Receivables - Net for 8 years, with the latest figure at $81.1 million in Q1 2026.

• Quarterly Receivables - Net rose 28.53% year-over-year to $81.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $81.1 million (up 28.53% YoY) and the FY2025 annual result came in at $74.0 million, up 17.44% from the prior year.
• Receivables - Net grew to $81.1 million in Q1 2026 per IMCR's latest filing, from $74.0 million in the prior quarter.
• Over five years, Receivables - Net peaked at $81.1 million in Q1 2026 and troughed at $48.3 million in Q3 2022.
• A 5-year average of $63.4 million and a median of $63.0 million in 2024 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net jumped 167.25% in 2022, then decreased 4.92% in 2023.
• Over 5 years, Receivables - Net stood at $54.8 million in 2022, then dropped by 4.92% to $52.1 million in 2023, then advanced by 20.95% to $63.0 million in 2024, then climbed by 17.44% to $74.0 million in 2025, then advanced by 9.59% to $81.1 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $81.1 million, $74.0 million, and $75.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.